Somebody on a forum will tell you that 1.0 mg of semaglutide is “about the same as” 7.5 mg of tirzepatide. Somebody else will offer a different pairing with equal confidence. Neither number exists.
There is no published equivalence between these molecules, because nobody has ever needed to establish one — they are different drugs acting on different receptor combinations, studied independently.
Why you cannot carry your dose across
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both the GLP-1 and the GIP receptor. They are not the same drug at different strengths; they are different mechanisms with partially overlapping effects.
Gastrointestinal tolerance is also molecule-specific and dose-specific. Having adapted to 2.4 mg of semaglutide tells you something encouraging about your general tolerance, but it does not mean your gut has met tirzepatide. Starting at 10 mg because you were “already at the top” reliably produces the vomiting that titration exists to prevent.
The manufacturer’s instruction is unambiguous: tirzepatide starts at 2.5 mg for four weeks, then climbs in 2.5 mg steps. There is no prior-exposure exemption in the labelling. The full ladders for all four drugs are in the GLP-1 dose charts.
The timing
One week. Take your last dose of the old drug on your usual day, and start the new one the following week on the same day.
This works because you are simply substituting one injection for another in a schedule you were already keeping. There is no washout requirement, and given semaglutide’s roughly week-long half-life there will be residual drug in your system for several weeks regardless — which cushions the transition rather than endangering it.
Longer gaps are occasionally used deliberately, usually when someone is switching because of side effects and wants them fully settled first. That is reasonable, at the cost of appetite returning in the interval.
2.5 mg
Starting tirzepatide dose after any semaglutide dose — no exceptions in the labelling
4–5 months
Time to climb back to a comparable dose position after switching
20 weeks
Time to climb from 2.5 mg to 15 mg at the minimum four-week interval
Reasons the switch is worth it
A better response. In SURPASS-2, a head-to-head trial in type 2 diabetes, tirzepatide outperformed semaglutide on both glycaemic and weight endpoints. SURMOUNT-5 compared them directly for obesity and again favoured tirzepatide on average weight loss. Average is doing work in that sentence — individual variation is enormous, and plenty of people do better on semaglutide. The comparison is unpacked in semaglutide versus tirzepatide and the head-to-head data.
A genuine plateau. If you have been at the maximum tolerated dose for several months and the scale has stopped, switching mechanism is a legitimate next move — though first read why weight loss stalls, because most plateaus are not drug failure.
Side effects that never settled. Some people tolerate one molecule and not the other, and the pattern is not predictable in advance.
Coverage or cost. Frequently the real reason. Formularies change annually, and the drug your plan preferred last year may not be this year’s — see what it costs and do you qualify.
Supply. Less pressing than it was, but the history is in shortages and compounding and, for readers outside the US, generic semaglutide abroad.
If the switch is being made for cost, the supplement side of the budget is worth reviewing too — see supplements for Ozempic and Wegovy and supplements for Zepbound and Mounjaro.
Switching is not an upgrade you unlock. It is starting a different drug, from the beginning, with everything that implies.
What to expect in the first month
Plan for it to feel like starting over, because it largely is.
Appetite suppression at 2.5 mg of tirzepatide will probably be weaker than what you had at a top semaglutide dose. This is temporary and it is where people panic and conclude the switch was a mistake — at week three, from the bottom of a ladder they have twenty weeks to climb.
Some weight regain during the transition is common and does not undo anything.
Side effects return, mildly. Nausea, and the constipation and reflux that come with any titration. Sulfur burps are more characteristic of tirzepatide than semaglutide, so that one may be new — see sulfur burps.
The practical business of a new pen also changes: a different device, a different needle, a different storage window — tirzepatide tolerates only 21 days at room temperature against semaglutide’s longer allowance.
Doing it properly
- Confirm the plan with your prescriber rather than switching between leftover pens at home
- Keep the same injection day, and note that tirzepatide requires 72 hours between doses if you later move the day, where semaglutide requires 48
- Do not overlap the two drugs
- Restart the injection site rotation from scratch — a new device is a good moment to fix technique
- Expect to be reassessed on dose at four weeks, not at one
The patience it requires
The transition costs you roughly four to five months to get back to a comparable dose, and most of the visible progress in that period will be regaining ground.
Which is worth knowing before you start, because the decision looks very different at week three than it did at week zero — and the people who abandon a switch almost all do it in that window.